Muramyl Dipeptide as a Therapeutic Agent for Inflammation

Description:
The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation of NOD2 by MDP negatively regulates the activity of TLR2, and thus reduces inflammation.

The inventors have demonstrated that administration of MDP prevents the development of experimental colitis in mice. They have also determined that MDP reduces pro-inflammatory cytokine production from multiple Toll-like receptors, and that this reduction arises from the induction of IFN regulatory factor 4 (IRF4). The technology includes methods of treating or preventing inflammation associated with an autoimmune disorder, particularly inflammatory bowel disease, via administration of muramyl peptide; also included are methods of reducing symptoms characteristic of inflammation via administration of muramyl peptide.
Patent Information:
For Information, Contact:
Charles Rainwater
Technology Development Specialist
NIH Technology Transfer
301-496-5717
crainwater@mail.nih.gov
Inventors:
Warren Strober
Keywords:
Autoimmune
AUTOIMMUNE DISEASE
Autoimmune disorder
Autoimmunity
BBXXXX
BCXXXX
BOWEL
Crohn disease; Inflammatory bowel disease 1
Crohn's disease
Dipeptide
IB3XXX
IBD
IBXXXX
IL-12
Inflammation
INFLAMMATORY
inflammatory bowel disease
Inflammatory bowel disease 1
inflammatory disease
INTERLEUKIN
INTERLEUKIN-12
IRF4
IXXXXX
MDP
Muramyl
NOD2
peptidoglycan
TLR
TLR2
Toll-like
Toll-like receptors
Ulcerative Colitis
© 2024. All Rights Reserved. Powered by Inteum